{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:07:46Z","timestamp":1795111666483,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Youth Program of National Natural Science Foundation of China","award":["81900182"],"award-info":[{"award-number":["81900182"]}]},{"name":"the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2021-I2M-C&T-B-080"],"award-info":[{"award-number":["2021-I2M-C&T-B-080"]}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["HH22KYZX0036"],"award-info":[{"award-number":["HH22KYZX0036"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Bloodstream infection (BSI) caused by Carbapenem-Resistant Enterobacteriaceae (CRE) are associated with poor outcomes in hematological patients. The aim of this study was to identify risk factors for mortality and evaluate the value of epidemiological feature of carbapenemases in guiding antimicrobial treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Hematological patients with monomicrobial CRE BSI between January 2012 and April 2021 were included. The primary outcome was all-cause mortality 30 days after BSI onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 94 patients were documented in the study period.\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      was the most common Enterobacteriaceae, followed by\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      . 66 CRE strains were tested for carbapenemase genes, and 81.8% (54\/66) were positive, including NDM (36\/54), KPC (16\/54), IMP (1\/54). Besides, one\n                      <jats:italic>E. coli<\/jats:italic>\n                      isolate was found to express both NDM and OXA-48-like genes. Overall, 28 patients received an antimicrobial treatment containing ceftazidime-avibactam (CAZ-AVI), of which 21 cases were combined with aztreonam. The remaining 66 patients were treated with other active antibiotics (OAAs). The 30-day mortality rate was 28.7% (27\/94) for all patients, and was only 7.1% ((2\/28) for patients treated with CAZ-AVI. In multivariate analysis, the presence of septic shock at BSI onset (OR 10.526, 95% CI 1.376\u201376.923) and pulmonary infection (OR 6.289, 95% CI 1.351\u201329.412) were independently risk factors for 30-day mortality. Comparing different antimicrobial regimens, CAZ-AVI showed a significant survive benefit than OAAs (OR 0.068, 95% CI 0.007\u20130.651).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      CAZ-AVI-containing regimen is superior to OAAs for CRE BSI. As the predominance of\n                      <jats:italic>bla<\/jats:italic>\n                      NDM in our center, we recommend the combination with aztreonam when choose CAZ-AVI.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12941-023-00586-y","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T21:01:58Z","timestamp":1684443718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options"],"prefix":"10.1186","volume":"22","author":[{"given":"Lining","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"issue":"1","key":"586_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119\u201323. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.12.002.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"586_CR2","doi-asserted-by":"publisher","unstructured":"Bodendoerfer E, Keller PM, Mancini S. Rapid identification of NDM-, KPC-, IMP-, VIM- and OXA-48-like carbapenemase-producing Enterobacteriales from blood cultures by a multiplex lateral flow immunoassay. The Journal of antimicrobial chemotherapy. 2019;74(6):1749-51. https:\/\/doi.org\/10.1093\/jac\/dkz056.","DOI":"10.1093\/jac\/dkz056"},{"key":"586_CR3","unstructured":"Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant Enterobacteriaceae(CRE), November 2015 update - CRE toolkit.Atlanta (GA) United States Department of Health and Human S.pdf."},{"issue":"45","key":"586_CR4","doi-asserted-by":"publisher","first-page":"e1931","DOI":"10.1097\/md.0000000000001931","volume":"94","author":"L Wang","year":"2015","unstructured":"Wang L, Wang Y, Fan X, Tang W, Hu J. Prevalence of resistant gram-negative Bacilli in bloodstream infection in Febrile Neutropenia Patients undergoing hematopoietic stem cell transplantation: a single Center Retrospective Cohort Study. Medicine. 2015;94(45):e1931. https:\/\/doi.org\/10.1097\/md.0000000000001931.","journal-title":"Medicine"},{"issue":"9","key":"586_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/bmt.2010.281","volume":"46","author":"Y Inamoto","year":"2011","unstructured":"Inamoto Y, Miyamura K, Okamoto S, Akiyama H, Iida H, Eto T, et al. Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies: a report from Japan Marrow Donor Program. Bone Marrow Transplant. 2011;46(9):1192\u2013202. https:\/\/doi.org\/10.1038\/bmt.2010.281.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"586_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/bmt.2014.231","volume":"50","author":"C Girmenia","year":"2015","unstructured":"Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50(2):282\u20138. https:\/\/doi.org\/10.1038\/bmt.2014.231.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"586_CR7","doi-asserted-by":"publisher","first-page":"106126","DOI":"10.1016\/j.ijantimicag.2020.106126","volume":"56","author":"H Seo","year":"2020","unstructured":"Seo H, Lee SC, Chung H, Ra SH, Sung H, Kim MN, et al. Clinical and microbiological analysis of risk factors for mortality in patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia. Int J Antimicrob Agents. 2020;56(4):106126. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106126.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"586_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dkaa503","volume":"76","author":"I Karaiskos","year":"2021","unstructured":"Karaiskos I, Daikos GL, Gkoufa A, Adamis G, Stefos A, Symbardi S, et al. Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. J Antimicrob Chemother. 2021;76(3):775\u201383. https:\/\/doi.org\/10.1093\/jac\/dkaa503.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"586_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","volume":"24","author":"M Falcone","year":"2020","unstructured":"Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24(1):29. https:\/\/doi.org\/10.1186\/s13054-020-2742-9.","journal-title":"Crit Care"},{"issue":"7","key":"586_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","volume":"55","author":"M Tumbarello","year":"2012","unstructured":"Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect diseases: official publication Infect Dis Soc Am. 2012;55(7):943\u201350. https:\/\/doi.org\/10.1093\/cid\/cis588.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"4","key":"586_CR11","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1128\/aac.02166-13","volume":"58","author":"GL Daikos","year":"2014","unstructured":"Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322\u20138. https:\/\/doi.org\/10.1128\/aac.02166-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"586_CR12","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/jac\/dkv086","volume":"70","author":"M Tumbarello","year":"2015","unstructured":"Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133\u201343. https:\/\/doi.org\/10.1093\/jac\/dkv086.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"586_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/s1473-3099(17)30228-1","volume":"17","author":"B Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B, Salamanca E, de Cueto M, Hsueh P-R, Viale P, Pa\u00f1o-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726\u201334. https:\/\/doi.org\/10.1016\/s1473-3099(17)30228-1.","journal-title":"Lancet Infect Dis"},{"key":"586_CR14","doi-asserted-by":"publisher","unstructured":"Machuca I, Guti\u00e9rrez-Guti\u00e9rrez B, Gracia-Ahufinger I, Rivera Espinar F, Cano \u00c1, Guzm\u00e1n-Puche J, et al. Mortality Associated with Bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. Antimicrob Agents Chemother. 2017;61(8). https:\/\/doi.org\/10.1128\/aac.00406-17.","DOI":"10.1128\/aac.00406-17"},{"issue":"2","key":"586_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: second-generation beta-Lactam\/beta-Lactamase inhibitor combinations. Clin Infect diseases: official publication Infect Dis Soc Am. 2016;63(2):234\u201341. https:\/\/doi.org\/10.1093\/cid\/ciw243.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"9","key":"586_CR16","doi-asserted-by":"publisher","first-page":"e0069821","DOI":"10.1128\/AAC.00698-21","volume":"65","author":"L Chen","year":"2021","unstructured":"Chen L, Han X, Li Y, Li M. Assessment of Mortality-Related risk factors and effective antimicrobial regimens for treatment of Bloodstream Infections caused by Carbapenem-Resistant Enterobacterales. Antimicrob Agents Chemother. 2021;65(9):e0069821. https:\/\/doi.org\/10.1128\/AAC.00698-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"586_CR17","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","volume":"73","author":"M Tumbarello","year":"2021","unstructured":"Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et al. Ceftazidime-Avibactam Use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a Retrospective Observational Multicenter Study. Clin Infect diseases: official publication Infect Dis Soc Am. 2021;73(9):1664\u201376. https:\/\/doi.org\/10.1093\/cid\/ciab176.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"2","key":"586_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin Versus Ceftazidime-Avibactam in the treatment of infections due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect diseases: official publication Infect Dis Soc Am. 2018;66(2):163\u201371. https:\/\/doi.org\/10.1093\/cid\/cix783.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"key":"586_CR19","doi-asserted-by":"publisher","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-Avibactam is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61(8). https:\/\/doi.org\/10.1128\/aac.00883-17.","DOI":"10.1128\/aac.00883-17"},{"key":"586_CR20","doi-asserted-by":"publisher","unstructured":"Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B et al. Can Ceftazidime-Avibactam and Aztreonam Overcome \u03b2-Lactam Resistance Conferred by Metallo-\u03b2-Lactamases in Enterobacteriaceae? Antimicrobial agents and chemotherapy. 2017;61(4). https:\/\/doi.org\/10.1128\/aac.02243-16.","DOI":"10.1128\/aac.02243-16"},{"issue":"11","key":"586_CR21","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in patients with bloodstream infections caused by Metallo-beta-lactamase-producing Enterobacterales. Clin Infect diseases: official publication Infect Dis Soc Am. 2021;72(11):1871\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa586.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"4","key":"586_CR22","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dkx496","volume":"73","author":"E Shaw","year":"2018","unstructured":"Shaw E, Rombauts A, Tubau F, Padull\u00e9s A, C\u00e0mara J, Lozano T, et al. Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73(4):1104\u20136. https:\/\/doi.org\/10.1093\/jac\/dkx496.","journal-title":"J Antimicrob Chemother"},{"key":"586_CR23","doi-asserted-by":"publisher","unstructured":"Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. Ceftazidime-Avibactam and Aztreonam, an interesting strategy to overcome \u03b2-Lactam resistance conferred by Metallo-\u03b2-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61(9). https:\/\/doi.org\/10.1128\/aac.01008-17.","DOI":"10.1128\/aac.01008-17"},{"issue":"9","key":"586_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/s1473-3099(13)70190-7","volume":"13","author":"LS Munoz-Price","year":"2013","unstructured":"Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785\u201396. https:\/\/doi.org\/10.1016\/s1473-3099(13)70190-7.","journal-title":"Lancet Infect Dis"},{"key":"586_CR25","doi-asserted-by":"publisher","first-page":"249856","DOI":"10.1155\/2014\/249856","volume":"2014","author":"L Dortet","year":"2014","unstructured":"Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int. 2014;2014:249856. https:\/\/doi.org\/10.1155\/2014\/249856.","journal-title":"Biomed Res Int"},{"issue":"1","key":"586_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijantimicag.2015.10.015","volume":"47","author":"A Potron","year":"2016","unstructured":"Potron A, Poirel L, Dortet L, Nordmann P. Characterisation of OXA-244, a chromosomally-encoded OXA-48-like \u03b2-lactamase from Escherichia coli. Int J Antimicrob Agents. 2016;47(1):102\u20133. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.10.015.","journal-title":"Int J Antimicrob Agents"},{"key":"586_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy660","author":"Q Wang","year":"2018","unstructured":"Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R, et al. Clinical infectious diseases: an official publication of the Infectious Diseases. Soc Am. 2018;67(suppl2):196\u2013S205. https:\/\/doi.org\/10.1093\/cid\/ciy660. Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012\u20132016."},{"key":"586_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","volume":"10","author":"R Han","year":"2020","unstructured":"Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. https:\/\/doi.org\/10.3389\/fcimb.2020.00314.","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-023-00586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-023-00586-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-023-00586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T21:02:14Z","timestamp":1684443734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-023-00586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1186\/s12941-023-00586-y","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}],"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2101714\/v1","asserted-by":"object"}]},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"25 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethical committee of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was attained from each participant in the study. It was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}